From: Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer
Reasons | Relevance to study 478 population |
---|---|
Short time to progression | 54% of patients in the trial had a treatment free interval (TFI) of ≤90 days |
Residual toxicity to first line regimen | 13% of patients in the best supportive care + topotecan arm and 10% in the best supportive care arm had residual toxicity |
Patient preference not to receive further intravenous chemotherapy | O'Brien et al report that some patients in the study with sensitive SCLC refuse further intravenous chemotherapy because of the risk of toxicity or become unsuitable for standard chemotherapy because of co-morbidities |